LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials
Researchers are increasingly focused on combination therapies and novel mechanisms of action that can enhance tumor response to treatment. LIXTE’s LB-100 is designed to sensitize cancer cells to chemotherapy and potentially enhance immune system activity, offering a complementary approach to existing treatments. The company recently announced the expansion of its ongoing clinical trial in clear cell ovarian cancer, including an increase in patient enrollment that effectively doubles the size of the study. Ovarian clear cell carcinoma and metastatic colon cancer remain among the most challenging malignancies to treat, with limited effective therapies and poor patient outcomes driving the urgent need…